MGTA News and Press, Magenta Therapeutics Inc. From 06/25/20

Magenta Therapeutics (NASDAQ: MGTA ) has priced its public offering of 7.5M common shares at $8.00/share, for expected gross proceeds of $60M. More news on: Magenta Therapeutics, Inc., Healthcare stocks news, , Read more ...

Magenta Therapeutics (NASDAQ: MGTA ) to offer $60M shares in an underwritten public offering, with underwriters having an option to purchase up to an additional 15% of the shares. More news on: Magenta Therapeutics, Inc., Healthcare stocks news, , Read more ...

Biogen Reports Positive Data from Landmark NURTURE Study Biogen Inc. ( BIIB ) reported new data from NURTURE which included nearly a year of additional follow-up for NURTURE study participants. It is the longest study of pre-symptomatic patients with spinal muscular atrophy. New data sho...

Magenta Therapeutics (NASDAQ: MGTA ) inks a non-exclusive research and clinical collaboration agreement with Beam Therapeutics (NASDAQ: BEAM ) to evaluate its antibody-drug conjugate (ADC) MGTA-117 for conditioning sickle cell disease and beta-thalassemia patients receiving the latter's ba...

– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeut...

Making a "strategic decision," Magenta Therapeutics (NASDAQ: MGTA ) will discontinue enrollment in a Phase 2 clinical trial evaluating MGTA-456 in patients with inherited metabolic disorders, deciding instead to focus its resources on stem cell mobilization and conditioning programs. M...

— MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic study in newly announced collaboration with National Marrow Donor Program® (NMDP)/Be The Match® — — MGTA-117 antibo...

Collaboration focuses on clinical development of MGTA-145 for stem cell mobilization in allogeneic transplant in patients with blood cancers Plan to initiate a Phase II trial of MGTA-145 in matched related donors for patients undergoing allogeneic transplant Magenta Therapeutics ...

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in a fireside chat and hold investor meetings at the 41 st annual Goldman...

-- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- MGTA-145 Phase 1 clinical data for stem cell mobilization provide a strong rationale for studying in patients with auto...